Your browser doesn't support javascript.
loading
ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis.
Lagares, David; Ghassemi-Kakroodi, Parisa; Tremblay, Caroline; Santos, Alba; Probst, Clemens K; Franklin, Alicia; Santos, Daniela M; Grasberger, Paula; Ahluwalia, Neil; Montesi, Sydney B; Shea, Barry S; Black, Katharine E; Knipe, Rachel; Blati, Meryem; Baron, Murray; Wu, Brian; Fahmi, Hassan; Gandhi, Rajiv; Pardo, Annie; Selman, Moisés; Wu, Jiangping; Pelletier, Jean-Pierre; Martel-Pelletier, Johanne; Tager, Andrew M; Kapoor, Mohit.
Affiliation
  • Lagares D; Division of Pulmonary and Critical Care Medicine, Fibrosis Research Center and Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Ghassemi-Kakroodi P; Department of Medicine, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Québec, Canada.
  • Tremblay C; Department of Medicine, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Québec, Canada.
  • Santos A; Division of Pulmonary and Critical Care Medicine, Fibrosis Research Center and Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Probst CK; Division of Pulmonary and Critical Care Medicine, Fibrosis Research Center and Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Franklin A; Division of Pulmonary and Critical Care Medicine, Fibrosis Research Center and Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Santos DM; Division of Pulmonary and Critical Care Medicine, Fibrosis Research Center and Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Grasberger P; Division of Pulmonary and Critical Care Medicine, Fibrosis Research Center and Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Ahluwalia N; Division of Pulmonary and Critical Care Medicine, Fibrosis Research Center and Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Montesi SB; Division of Pulmonary and Critical Care Medicine, Fibrosis Research Center and Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Shea BS; Division of Pulmonary and Critical Care Medicine, Fibrosis Research Center and Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Black KE; Division of Pulmonary and Critical Care Medicine, Fibrosis Research Center and Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Knipe R; Division of Pulmonary and Critical Care Medicine, Fibrosis Research Center and Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Blati M; Department of Medicine, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Québec, Canada.
  • Baron M; Division of Rheumatology, Jewish General Hospital, McGill University, Montreal, Québec, Canada.
  • Wu B; The Arthritis Program, University Health Network, Toronto, Ontario, Canada.
  • Fahmi H; Department of Medicine, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Québec, Canada.
  • Gandhi R; The Arthritis Program, University Health Network, Toronto, Ontario, Canada.
  • Pardo A; Facultad de Ciencias, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico.
  • Selman M; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City, Mexico.
  • Wu J; Department of Medicine, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Québec, Canada.
  • Pelletier JP; Department of Medicine, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Québec, Canada.
  • Martel-Pelletier J; Department of Medicine, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Québec, Canada.
  • Tager AM; Division of Pulmonary and Critical Care Medicine, Fibrosis Research Center and Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Kapoor M; Department of Medicine, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Québec, Canada.
Nat Med ; 23(12): 1405-1415, 2017 Dec.
Article in En | MEDLINE | ID: mdl-29058717
ABSTRACT
Maladaptive wound healing responses to chronic tissue injury result in organ fibrosis. Fibrosis, which entails excessive extracellular matrix (ECM) deposition and tissue remodeling by activated myofibroblasts, leads to loss of proper tissue architecture and organ function; however, the molecular mediators of myofibroblast activation have yet to be fully identified. Here we identify soluble ephrin-B2 (sEphrin-B2) as a new profibrotic mediator in lung and skin fibrosis. We provide molecular, functional and translational evidence that the ectodomain of membrane-bound ephrin-B2 is shed from fibroblasts into the alveolar airspace after lung injury. Shedding of sEphrin-B2 promotes fibroblast chemotaxis and activation via EphB3 and/or EphB4 receptor signaling. We found that mice lacking ephrin-B2 in fibroblasts are protected from skin and lung fibrosis and that a disintegrin and metalloproteinase 10 (ADAM10) is the major ephrin-B2 sheddase in fibroblasts. ADAM10 expression is increased by transforming growth factor (TGF)-ß1, and ADAM10-mediated sEphrin-B2 generation is required for TGF-ß1-induced myofibroblast activation. Pharmacological inhibition of ADAM10 reduces sEphrin-B2 levels in bronchoalveolar lavage and prevents lung fibrosis in mice. Consistent with the mouse data, ADAM10-sEphrin-B2 signaling is upregulated in fibroblasts from human subjects with idiopathic pulmonary fibrosis. These results uncover a new molecular mechanism of tissue fibrogenesis and identify sEphrin-B2, its receptors EphB3 and EphB4 and ADAM10 as potential therapeutic targets in the treatment of fibrotic diseases.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin / Skin Diseases / Ephrin-B2 / Amyloid Precursor Protein Secretases / Idiopathic Pulmonary Fibrosis / Myofibroblasts / ADAM10 Protein / Lung / Membrane Proteins Type of study: Prognostic_studies Limits: Animals Language: En Journal: Nat Med Year: 2017 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin / Skin Diseases / Ephrin-B2 / Amyloid Precursor Protein Secretases / Idiopathic Pulmonary Fibrosis / Myofibroblasts / ADAM10 Protein / Lung / Membrane Proteins Type of study: Prognostic_studies Limits: Animals Language: En Journal: Nat Med Year: 2017 Document type: Article